成都麻沸散医药科技

Chengdu Mafeisan Pharmaceutical Technology is a clinical-stage biotechnology company focused on the development of next-generation anesthetic and analgesic drugs. Based in Chengdu, China, the company was established to commercialize research originating from the West China Hospital of Sichuan University, particularly in the field of perioperative medicine. Its primary focus is on creating safer, more effective small molecule anesthetics that provide rapid onset and recovery with minimal cardiovascular or respiratory depression. The company's lead candidate, MFS-1502, is currently being evaluated in clinical trials for general anesthesia and procedural sedation.